Latest Health News

Tag: swiss

  • Novartis CEO plays down prospects for Actelion bid: Blick

    —

    by

    publisher
    in

    Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: “We have always said that we…

  • Novartis CEO plays down prospects for Actelion bid: Blick

    —

    by

    elegant
    in

    Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: “We have always said that we…

  • J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg

    —

    by

    publisher
    in

    (Reuters) – U.S. healthcare company Johnson & Johnson has approached Swiss biotechnology firm Actelion Ltd about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter. The report said deliberations were still at an early stage following Johnson & Johnson's (J&J) initial offer, and Actelion was working with an…

  • Knife-wielding attacker wounds seven children in China

    —

    by

    contributor
    in

    A knife-wielding man on Friday wounded seven children and two bystanders outside a primary school in northwestern China, state media said, in the latest mass knifing attack. Violent crime is rare in China compared with many other countries, but there has been a series of knife and ax attacks in recent years, many targeting children.…

  • The Novartis house that Vasella built gets extreme makeover

    —

    by

    creative
    in

    By John Miller ZURICH (Reuters) – Signals from Swiss drugmaker Novartis that it could unload its struggling Alcon eyecare business is the latest step in dismantling former leader Dan Vasella's vision of building a European healthcare giant. Chairman Joerg Reinhardt said at the weekend that Alcon's woes have intensified soul-searching over the unit's future. “All…

  • Novartis psoriasis drug maintains efficacy after four years: study

    —

    by

    admin
    in

    Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson. More than 66 percent of Cosentyx patients achieved “clear or almost clear” skin after…

  • FDA panel supports Novartis version of Amgen arthritis drug

    —

    by

    creative
    in

    Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 20-O that there is no clinically meaningful difference between Novartis's drug, a biologic made of…

  • U.S. sends 47 troops to South Sudan to protect Americans

    —

    by

    publisher
    in

    The White House said on Wednesday that it had deployed 47 troops to South Sudan to protect U.S. citizens and the U.S. embassy after an outbreak of deadly violence in the country. “These deployed personnel will remain in South Sudan until the security situation becomes such that their presence is no longer needed,” the White…

  • UBS, MPM team up on $471 million cancer fund to speed drug development

    —

    by

    admin
    in

    (Corrects minimum commitment to $200,000 from $500,000 figure given by UBS on Wednesday) ZURICH (Reuters) – A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy…